Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Last Updated: Thursday, July 10, 2025

Investigators conducted whole-genome shotgun sequencing on stool samples from patients with multiple myeloma undergoing idecabtagene vicleucel (ide-cel) administration. They found a significant decrease in bacterial diversity following ide-cel infusion. Additionally, there were significant differences in bacterial composition, which were linked to therapy response and toxicities.

Blood Advances

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

CAR T-Cell Therapy Resource Center

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

Fast Facts #12: BCMA Targets